Chemico-biological interactions
Cure8 research brief
Why This Matters
The study suggests a natural flavonoid (DHQ) can protect against DSS-induced colitis in mice and identifies a specific phospholipase-related pathway that may link phospholipid breakdown to epithelial barrier disruption—potentially pointing to new mechanistic targets for IBD research.
Who Should Pay Attention
Researchers, translational scientists, and clinicians interested in IBD mechanisms, lipid metabolism, and preclinical therapeutic leads
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The study used DSS-treated mice to model colitis and tested oral DHQ and fecal microbiota transplantation (FMT). Both interventions improved colitis signs, inflammation, and epithelial barrier measures in the model.
The authors combined transcriptomics, metabolomics, network pharmacology, molecular docking, and follow-up molecular experiments to identify a pathway (PPARγ/AVPR1A/PLCB1/PLA2) and altered phospholipid metabolism as candidate mechanisms. The work is preclinical (mouse model and in silico/biochemical analyses).
It highlights a possible protective mechanism of DHQ and a metabolic pathway worth further study, but it does not demonstrate safety or effectiveness in humans.
Keep In Mind
Findings come from a preclinical mouse model (DSS-induced colitis) and integrated omics and computational analyses; human relevance is not established.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationChemico-biological interactions
AuthorsJunxi Pan, Jing Yang, Liu Tang +5 more
InstitutionDepartment of Clinical Laboratory, the First Affiliated Hospital of Kunming Medical University & Yunnan Key Laboratory of Laboratory Medicine & Yunnan Province Clinical Research Center for Laboratory Medicine, Kunming, 650032, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedAug 10, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declaration of Competing Interest The whole authors declared that there are no conflicts of interest between them.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Poricoic acid a ameliorates ulcerative colitis via AMPK/PPARγ pathway-dependent cellular senescence inhibition and concomitant gut microbiota-metabolome modulation.
This study identifies a plant-derived compound (poricoic acid A) that reduced inflammation, cellular senescence, and colon injury in cell and mouse models of ulcerative colitis and links those effects to AMPK/PPARγ...
Rhoifolin Alleviates Ulcerative Colitis by Targeting NMNAT1 and Activating SIRT1‐FOXO1 Signaling to Enhance ILC3s Effector Function
The paper describes a new immunometabolic mechanism that strengthened intestinal barrier function and reduced colitis in mice, suggesting a potential pathway to develop therapies that boost ILC3-driven IL-22 production...
Changyanqing decoction ameliorates ulcerative colitis via PI3K-Akt pathway: Insights from network pharmacology and in-vitro validation.
Patients and clinicians often ask whether herbal formulas or plant compounds can help IBD. This preclinical study identifies quercetin and the PI3K–Akt pathway as potential mechanisms, which may guide future research...